



Innovative Medicines Initiative

Welcome and introduction to IMI

Andrzej Jan Rys

*Directorate-General for Health and Consumers,
European Commission,
IMI Governing Board*




Eurobiotech, Krakow, 12 October 2011


Why IMI?




- Decline in R&D industrial productivity despite steadily increasing R&D expenditures
 - => research bottlenecks in the drug development process
- Loss of European competitiveness in the sector
- Europe is good at putting stakeholders together, based on the EU experience from the Framework Programmes
- Europe has the potential and capacity of innovation, based on a tissue of entrepreneurial universities and SMEs
- Common initiative EC – Pharma industry
- Faster and better drugs for the patient



IMI Objectives




Better and faster medicines for patients





IMI particular features


- Problem-solving approach and precompetitive research
- Potential to address unmet medical needs (“unlock” a specific area)
- Dialogue with the regulatory authorities
- Work beyond usual habits
 - Participation to large and new types of partnerships.
 - Data and knowledge sharing at larger scale.
- New research tools to be rapidly and broadly spread and taken up within the scientific and industrial community
 - A tailor-made IMI intellectual property policy provides the adequate provisions to support this challenge



What do we expect for IMI




- Address open innovation
 - Address unmet Medical needs
 - Guarantee uptake of new scientific and industrial precompetitive research tools
 - Tool to reinvigorate drug development for the benefit of patients
 - Consolidate research networks and PP collaboration
-



What is achieved



- 2 calls implemented :
 - 23 projects running in 2011 with ~190M€ from IMI JU and ~200 M€ from EFPIA companies
- 3rd call projects under negotiation
- 4th Call launched in July 2011
- Update of scientific research agenda summer 2011
- Solid reflection on remaining Calls engaged
- Interim evaluation of IMI JU finalised




SME involvement in IMI projects



	Number of SME	SME funding	Total Funding	%
Call 1	25	14.602.472	109.593.433	13,32%
Call 2	22	15.455.411	80.740.072	19,14%
Call 1 and 2	47	30.057.883	190.333.505	15,79%

SMEs involved in all projects except the education and training projects from the first call




What next?



**IMI 4th Call (2011) closing date 18 October 2011,
particular effort on Knowledge Management**

The remaining calls will bring:


- **Larger projects for some topics**
- **Special focus on knowledge management to harness the wealth of data generated by IMI projects**



Outlook




- **Innovation at the heart of the Europe 2020 strategy for growth and jobs : Innovation Union**
- **Commission green paper on a Common Strategic Framework for European research:**
 - Focus on world-beating science base, boosting competitiveness, tackling grand challenges such as health and ageing population
 - Making EU funding more attractive and easier to access; funding instruments covering the full innovation chain, including basic research, applied research, collaboration between academia and industry and firm-level innovation
 - Simpler and more consistent accounting procedures for use of funds
- Commission will make legislative proposal before end of 2011
- Part of the 2014-2020 multiannual financial framework



What about the future?



- Harvesting on the results from ongoing projects
 - Define performance indicators and assess impact of IMI.
 - Define « IdealHouse » for PPP. How does/will IMI fit in this?
 - What about IMI.2? If any, what would it look like?
-



More about IMI: www.imi.europa.eu



Contact Newsletter Links



Innovative Medicines Initiative

Click here for site menu

Search:



IMI 4th Call officially launched

IMI has formally launched its 4th Call for proposals. Details of the topics and information on how to apply can be found [here](#)

Promote the 4th Call with the info pack [here](#)

IMI NEWSFLASH

19/09/2011 : IMI has opened the online submission tool for Expressions of Interest to IMI's 4th Call:
<http://t.co/SLbGF8my> Deadline = 18 October 2011.

01/09/2011 : New! Questions and answers on the IMI 4th Call topics are now online at <http://t.co/8rCq9Dz>

[Follow us on Twitter](#)

ABOUT IMI



The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients.

IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.



[more](#)

IMI at the European Parliament

Join IMI and the other Joint Technology Initiatives in Brussels on 6 October to find out how they are successfully driving innovation. [more](#)

IMI at Eurobiotech

Join IMI on 12 October for an event in Krakow, Poland on 'IMI - New opportunities for drug research in Europe'. [more](#)

PRESS RELEASES & MEDIA

[more](#)

NEWSLETTER

[Subscribe to the IMI newsletter](#)


FINDING PARTNERS

IMI has updated its Partner Search e-tool which now provides direct links to potential partners for people interested in finding possible partners in

VISIT IMI'S ONGOING PROJECTS

IMI currently funds 23 projects with a combined budget of over €450 million and covering drug safety and efficacy, knowledge

IMI VIDEOS



WEB UPDATES

- IMI launches 4th Call for proposals
- IMI Open Info Day videos are available now

